5th Generation of Iran-Made Software Meets Users’ Needs
11:17 - January 18, 2023

5th Generation of Iran-Made Software Meets Users’ Needs

TEHRAN (ANA)- A knowledge-based company in Iran launched the production line of the fifth-generation software to meet the needs of users and organizations in the country.
News ID : 1360

“The production line of the fifth generation of software helps development of the most up-to-date software inside the country and meeting the domestic needs,” said Babak Vaziri, the managing director of the knowledge-based company.

He noted that the production line of the fifth generation of software enjoys a fully Iranian design.

“In production line of the fifth generation of Iran-made software, we have been able to design other software without coding which plays a significant role in reducing costs,” Vaziri said.

In a relevant development earlier this year, Iranian researchers at Amirkabir University of Technology succeeded in developing a software package to determine the optimal treatment plan (including the dose and timing of chemotherapy and radiation therapy) based on the specific conditions of each patient.

 “The aim of this research is to provide a software package for designing a treatment plan (including dosage and timing of chemotherapy and radiation therapy), specifically for patients with glioblastoma, which helps doctors and specialists as a decision aid in finding the optimal treatment,” said Amir Ebrahimizadeh, one of the researchers of the project at Amirkabir University of Technology.

He added that the standard treatment of glioblastoma is a combination of radiotherapy and temozolomide, noting that since separate planning of each of them leads to ignoring the effects of the other method and obtaining unreliable results, the present research is unique in its kind.

“Results of the research showed that performance of the personal treatment planning enjoys significant superiority over the common standard treatment program,” Ebrahimizadeh said.

He added that simulation of the personal treatment program on 271 patients participating in the EORTC clinical trial shows that in 237 cases, following the optimal personal program compared to the standard program had a greater effect on reducing the tumor size and improving disease symptoms.

“Also, in 34 cases, the size of the tumor after following the personal treatment program and the standard program was equal,” the researcher said.

4155/v

 

 

 

Send comment